Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Wee

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Science Translational Medicine|October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunityMichael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Journal of Medicinal Chemistry|September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignAshvinikumar V Gavai, Derek Norris, George Delucca, et al.
Journal of Medicinal Chemistry|October 14, 2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Denise C Grünenfelder, Upender Velaparthi, Jayakumar S Warrier, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|February 7, 2024
Discovery of (4-Pyrazolyl)-2-aminopyrimidines as Potent and Selective Inhibitors of Cyclin-Dependent Kinase 2Joshua R Hummel, Kai-Jiong Xiao, Jeffrey C Yang, et al.
Science Translational Medicine|October 25, 2023
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunityMichael Wichroski, Joseph Benci, Si-Qi Liu, et al.
Journal of Medicinal Chemistry|September 20, 2021
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug DesignAshvinikumar V Gavai, Derek Norris, George Delucca, et al.
Journal of Medicinal Chemistry|October 14, 2025
Design, Synthesis, and T Cell Checkpoint Combination Potential Of First-In-Class DGKα/ζ Inhibitor BMS-986408Denise C Grünenfelder, Upender Velaparthi, Jayakumar S Warrier, et al.
Pageof 3